Table 4 Comparison of Pneumocystis jirovecii pneumonia according to occurrence time.
Early PJP (n = 25) | Late PJP (n = 25) | P value | |
|---|---|---|---|
Age at transplantation (years) | 47.0 ± 14.5 | 55.2 ± 11.4 | 0.055 |
Sex (female) | 6 (24.0%) | 14 (56.0%) | 0.021 |
BMI (kg/m2) | 22.72 ± 0.77 | 20.90 ± 0.55 | 0.060 |
Hemoglobin (g/dL) | 11.02 ± 1.60 | 10.24 ± 2.17 | 0.154 |
Delayed graft function | 2 (8.0%) | 2 (8.0%) | 0.434 |
Re-transplantation, n (%) | 2 (8.0%) | 1 (4.0%) | 0.552 |
Desensitization, n (%) | 11 (44.0%) | 8 (32.0%) | 0.561 |
Number of HLA mismatch | 3.6 ± 1.4 | 3.8 ± 1.4 | 0.554 |
ATG use, n (%) | 2 (8.0%) | 5 (20.0%) | 0.417 |
Tacrolimus dose at discharge (mg) | 7.67 ± 5.14 | 6.97 ± 0.99 | 0.328 |
Tacrolimus dose per body weight at discharge (mg/kg) | 0.12 ± 0.02 | 0.13 ± 0.02 | 0.402 |
Tacrolimus level at discharge (mg/dL) | 8.91 ± 0.58 | 7.18 ± 0.64 | 0.051 |
Formulation of tacrolimus, n (%) | 0.213 | ||
Once daily | 0 (0.0%) | 0 (0.0%) | |
Twice daily | 21 (84.0%) | 16 (64.0%) | |
Unknown | 4 (16.0%) | 9 (36.0%) | |
Tacrolimus conversion (twice to once daily), n (%) | 1 (4.0%) | 0 (0.0%) | 0.455 |
Steroid use at discharge | 24 (96.0%) | 25 (100.0%) | 1.000 |
MMF use at discharge | 23 (92.0%) | 23 (92.0%) | 1.000 |
mTORi use at discharge | 1 (4.0%) | 1 (4.0%) | 1.000 |
PJP Prophylaxis, n (%) | 25 (100.0%) | 25 (100.0%) | 1.000 |
Dose of prophylactic TMP-SMP, n (%) | 0.755 | ||
1 Single strength/day | 24 (96.0%) | 24 (96.0%) | |
1 Double strength/day | 1 (4.0%) | 1 (4.0%) | |
Duration of PJP prophylaxis (months) | 6.1 ± 1.4 | 5.9 ± 0.6 | 0.572 |
Time from transplantation to PJP (months) | 3.24 ± 1.48 | 13.60 ± 7.67 | < 0.001 |
PJP during PJP prophylaxis, n (%) | 24 (96.0%) | 3 (6.0%) | < 0.001 |
Graft rejection before PJP, n (%) | 5 (20.0%) | 8 (32.0%) | 0.520 |
Time from rejection to PJP (months) | 3.2 ± 0.8 | 7.4 ± 3.8 | 0.045 |
CMV infection before PJP, n (%) | 0 (0.0%) | 1 (4.0%) | 0.500 |
Graft loss, n (%) | 3 (12.0%) | 1 (4.0%) | 0.609 |
Death, n (%) | 5 (20.0%) | 4 (16.0%) | 0.500 |
Death due to PJP, n (%) | 3 (12.0%) | 4 (16.0%) | 0.500 |
